Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neoplasms 2Stomach Neoplasms 1Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Complications 1Noncommunicable Diseases 1Neoplasms, Squamous Cell 1Neoplasms, Basal Cell 1Melanoma 1Lymphatic Abnormalities 1Lymphangioma 1Ischemic Stroke 1Chronic Disease 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1Brain Neoplasms 1Abdomen, Acute 1

Interventions

Cisplatin 55Radiotherapy 33Cetuximab 25Paclitaxel 23Carboplatin 23Radiotherapy, Intensity-Modulated 21pembrolizumab 19Docetaxel 17Fluorouracil 16Nivolumab 14Drug Therapy 11Radiation 9Erlotinib Hydrochloride 8Blood Specimen Collection 8durvalumab 7Magnetic Resonance Spectroscopy 7Surveys and Questionnaires 6atezolizumab 5Surgical Procedures, Operative 5Radiosurgery 5Esophagectomy 5Chemoradiotherapy 5olaparib 4dacomitinib 4Leucovorin 4Cyclophosphamide 4Capecitabine 4Biopsy 4Afatinib 4fludarabine phosphate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Squamous Cell × Risk Factors × Clear all
NCT03509467 2025-12-19

Using MC1R Genotype to Impact Melanoma Risk Behavior

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
2,054 enrolled 92 charts
Dermatologic

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasms, Neoplasms, Basal Cell, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡